0001411690-24-000035.txt : 20240620
0001411690-24-000035.hdr.sgml : 20240620
20240620162304
ACCESSION NUMBER: 0001411690-24-000035
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240618
FILED AS OF DATE: 20240620
DATE AS OF CHANGE: 20240620
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vuori Kristiina MD
CENTRAL INDEX KEY: 0001612627
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38613
FILM NUMBER: 241056578
MAIL ADDRESS:
STREET 1: C/O WEBMD HEALTH CORP.
STREET 2: 111 EIGHTH AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10011
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bionano Genomics, Inc.
CENTRAL INDEX KEY: 0001411690
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 261756290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9540 TOWNE CENTRE DRIVE
STREET 2: SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (858) 888-7600
MAIL ADDRESS:
STREET 1: 9540 TOWNE CENTRE DRIVE
STREET 2: SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Bionano Genomics, Inc
DATE OF NAME CHANGE: 20190308
FORMER COMPANY:
FORMER CONFORMED NAME: BioNano Genomics, Inc
DATE OF NAME CHANGE: 20120703
FORMER COMPANY:
FORMER CONFORMED NAME: BioNanomatrix Inc
DATE OF NAME CHANGE: 20070906
4
1
wk-form4_1718914977.xml
FORM 4
X0508
4
2024-06-18
0
0001411690
Bionano Genomics, Inc.
BNGO
0001612627
Vuori Kristiina MD
C/O BIONANO GENOMICS, INC.
9540 TOWNE CENTRE DRIVE, SUITE 100
SAN DIEGO
CA
92121
1
0
0
0
0
Stock Option (Right to Buy)
0.7752
2024-06-18
4
A
0
30000
0
A
2034-06-18
Common Stock
30000
30000
D
The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan).
/s/ R. Erik Holmlin, Attorney-in-Fact
2024-06-20